Can a New Dietary Supplement Help Minimise the Risk of Breast Cancer?
In the UK, about 1 in 8 women will develop breast cancer at some point during their lifetime. While there is no guaranteed way to prevent the disease, there are steps that may help lower the risk — especially for those at an increased risk of developing breast cancer.
As well as leading a healthy diet and lifestyle, women who are at risk or worried about breast cancer may be able to lower their chances of developing it, by supplementing their diet with a revolutionary new supplement, ProfBiotics Breast. Welcomed by leading cancer experts, it has been developed in consultation with Professor Martyn Caplin, leading cancer specialist and consultant gastroenterologist at London’s Royal Free Hospital, following a comprehensive review of clinical evidence investigating the role of specific nutrients in breast cancer prevention.
The supplement has been formulated to contain the specific blend of ingredients to help support breast wellbeing:
• Lycopene (tomato powder 5 mg), which has been increasingly associated with breast well-being. Studies suggest that women with higher circulating levels of lycopene may be at reduced risk of breast cancer
• Vitamin D (12.5 mcg [500 IU]), which has been found to regulate cell death – data suggest there is an association between lower levels of vitamin D and higher rates of breast cancer
• Zinc ([from Citrate] 7.5mg) — studies find that low zinc intake may be linked to breast cancer risk
• Curcumin (extract 25:1 — 240 mg providing 6000 mg whole herb equivalent) , which appears to be useful in preventing human breast cancer development.
The formula contains the equivalent of eight teaspoons of turmeric which would be difficult to consume each day through diet alone.
Cancer experts have welcomed the initiative. Justin Stebbing, Professor of Cancer Medicine and Oncology at Imperial College London, comments, “Any approach which may help reduce cancer risk utilising diet and appropriate nutrients is of huge potential value for individuals and society. The combinations used in these products are in line with the results of scientific research studying different tumour types and represent a new approach to tackling cancer incidence through diet and nutrient supplementation. The formulations may also have a role during and after cancer treatment for nutritional support, and to counter adverse effects of chemotherapies.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.